Stem cell technology company NeoStem's (AMEX:NBS) Amorcyte unit was featured in a TV news item Monday on New York's CBS 2 channel.
The news item featured a patient who underwent Amorcyte's Phase I trial of AMR-001.
AMR-001 is an autologous cell therapy designed to prevent heart tissue damage and further major adverse cardiac events following a heart attack. The treament consists of a patient's own bone marrow cells, which are processed to create pharmaceutical-grade cells that are then re-injected through coronary arteries into damaged areas of the heart, 6 to 11 days after a patient experiences a heart attack.
Because the treatment is autologous, meaning cells are taken from the same individual that they're transplanted into, it has no risk of rejection and can provide support for an extended period of time.
Dr Arshed Quyyumi of the Emory University of Medicine said in the news segment that the phase I treatment led to "improved blood supply".
In a Phase I study, AMR–001 was shown to be safe and the threshold dose for efficacy was isolated. The treatment has an accessible market of over $1.2 billion per annum.
Based on the success of Phase I, Amorcyte expects a Phase II trial to be approved.
The Phase II trial will include 230 patients in approximately 30 sites. The company has commitments from leading US research hospitals to participate in the phase II trial, including Emory, Vanderbilt and the Mayo Clinic.
The video can be seen here: